QVIDTVM Management LLC Has $34.67 Million Position in Solventum Co. (NYSE:SOLV)

QVIDTVM Management LLC raised its position in Solventum Co. (NYSE:SOLV) by 13.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 497,276 shares of the company’s stock after acquiring an additional 59,059 shares during the period. Solventum makes up about 24.3% of QVIDTVM Management LLC’s holdings, making the stock its 2nd largest position. QVIDTVM Management LLC’s holdings in Solventum were worth $34,670,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Price T Rowe Associates Inc. MD acquired a new stake in shares of Solventum in the 1st quarter worth about $5,889,000. CWM LLC bought a new position in shares of Solventum in the second quarter valued at approximately $473,000. Great Valley Advisor Group Inc. purchased a new position in shares of Solventum during the second quarter valued at approximately $493,000. First Horizon Advisors Inc. bought a new stake in Solventum during the second quarter worth $58,000. Finally, Swedbank AB purchased a new stake in Solventum in the 2nd quarter valued at $4,711,000.

Solventum Trading Up 1.1 %

Shares of SOLV stock opened at $71.58 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a 50 day moving average of $70.52 and a 200-day moving average of $62.35. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SOLV shares. Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler upped their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. BTIG Research initiated coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Finally, Wells Fargo & Company dropped their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.